The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
OBJECTIVES: To describe associations between different summaries of adherence in the first year on antiretroviral therapy (ART) and the subsequent risk of mortality, to identify patients at high risk because of early adherence behaviour. METHODS: We previously described an approach where adherence b...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797068744511455232 |
|---|---|
| author | Kiwuwa-Muyingo, S Walker, A Oja, H Levin, J Miiro, G Katabira, E Kityo, C Hakim, J Todd, J |
| author_facet | Kiwuwa-Muyingo, S Walker, A Oja, H Levin, J Miiro, G Katabira, E Kityo, C Hakim, J Todd, J |
| author_sort | Kiwuwa-Muyingo, S |
| collection | OXFORD |
| description | OBJECTIVES: To describe associations between different summaries of adherence in the first year on antiretroviral therapy (ART) and the subsequent risk of mortality, to identify patients at high risk because of early adherence behaviour. METHODS: We previously described an approach where adherence behaviour at successive clinic visits during the first year on ART was seen as a Markov chain (MC), and the individually estimated transition probabilities between 'good', 'poor' and 'non-response' adherence states were used to classify HIV-infected adults in the DART trial into subgroups with similar behaviour. The impact of this classification and classifications based on traditional 'averaged' measures [mean drug possession ratio (DPR) and self-reported adherence] were compared in terms of their impact on longer-term mortality over the 2-5 years on ART using Cox proportional hazards models. RESULTS: Of 2960 participants in follow-up after 1 year on ART, 29% had never missed pills in the last month and 11% had 100% DPR throughout the first year. The poorest adherers by self-reported measures were more likely to have only none/primary education (P < 0.01). Being in the poorest adherence subgroup by MC and DPR was independently associated with increased mortality [HR = 1.57 (95% CI 1.02, 2.42); 1.82 (1.32, 2.51) respectively]. CONCLUSIONS: Classification based on dynamic adherence behaviour is associated with mortality independently of DPR. The classifications could be useful in understanding adherence, targeting focused interventions and improving longer-term adherence to therapy. |
| first_indexed | 2024-03-06T22:14:31Z |
| format | Journal article |
| id | oxford-uuid:52f215fd-69b7-47ee-99ee-d1b97fc828da |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:14:31Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:52f215fd-69b7-47ee-99ee-d1b97fc828da2022-03-26T16:28:35ZThe impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:52f215fd-69b7-47ee-99ee-d1b97fc828daEnglishSymplectic Elements at Oxford2012Kiwuwa-Muyingo, SWalker, AOja, HLevin, JMiiro, GKatabira, EKityo, CHakim, JTodd, JOBJECTIVES: To describe associations between different summaries of adherence in the first year on antiretroviral therapy (ART) and the subsequent risk of mortality, to identify patients at high risk because of early adherence behaviour. METHODS: We previously described an approach where adherence behaviour at successive clinic visits during the first year on ART was seen as a Markov chain (MC), and the individually estimated transition probabilities between 'good', 'poor' and 'non-response' adherence states were used to classify HIV-infected adults in the DART trial into subgroups with similar behaviour. The impact of this classification and classifications based on traditional 'averaged' measures [mean drug possession ratio (DPR) and self-reported adherence] were compared in terms of their impact on longer-term mortality over the 2-5 years on ART using Cox proportional hazards models. RESULTS: Of 2960 participants in follow-up after 1 year on ART, 29% had never missed pills in the last month and 11% had 100% DPR throughout the first year. The poorest adherers by self-reported measures were more likely to have only none/primary education (P < 0.01). Being in the poorest adherence subgroup by MC and DPR was independently associated with increased mortality [HR = 1.57 (95% CI 1.02, 2.42); 1.82 (1.32, 2.51) respectively]. CONCLUSIONS: Classification based on dynamic adherence behaviour is associated with mortality independently of DPR. The classifications could be useful in understanding adherence, targeting focused interventions and improving longer-term adherence to therapy. |
| spellingShingle | Kiwuwa-Muyingo, S Walker, A Oja, H Levin, J Miiro, G Katabira, E Kityo, C Hakim, J Todd, J The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. |
| title | The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. |
| title_full | The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. |
| title_fullStr | The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. |
| title_full_unstemmed | The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. |
| title_short | The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. |
| title_sort | impact of first year adherence to antiretroviral therapy on long term clinical and immunological outcomes in the dart trial in uganda and zimbabwe |
| work_keys_str_mv | AT kiwuwamuyingos theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT walkera theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT ojah theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT levinj theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT miirog theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT katabirae theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT kityoc theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT hakimj theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT toddj theimpactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT kiwuwamuyingos impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT walkera impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT ojah impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT levinj impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT miirog impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT katabirae impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT kityoc impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT hakimj impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe AT toddj impactoffirstyearadherencetoantiretroviraltherapyonlongtermclinicalandimmunologicaloutcomesinthedarttrialinugandaandzimbabwe |